Key result
Multi-omics approaches reveal molecular mechanisms and potential biomarkers for PAH-CHD.
Why the study?
PAH-CHD is a severely progressive condition with an uncertain physiological course, making it relevant to clarify molecular modification mechanisms to identify treatment strategies.
This review highlights the potential of multi-omics technologies in discovering biomarkers and understanding the molecular pathogenesis of PAH-CHD.
Supports multi-omics research in PAH-CHD; leaves open clinical adoption pending prospective validation.
Pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) is a severely progressive condition with uncertain physiological course. Hence, it has become increasingly relevant to clarify the specific mechanisms of molecular modification, which is crucial to identify more treatment strategies. With the rapid development of high-throughput sequencing, omics technology gives access to massive experimental data and advanced techniques for systems biology, permitting comprehensive assessment of disease occurrence and progression. In recent years, significant progress has been made in the study of PAH-CHD and omics. To provide a comprehensive description and promote further in-depth investigation of PAH-CHD, this review attempts to summarize the latest developments in genomics, transcriptomics, epigenomics, proteomics, metabolomics, and multi-omics integration.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2023) conducted a review in Pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD). Multi-omics approaches, including genomics, transcriptomics, epigenomics, proteomics, and metabolomics, provide comprehensive insights into the molecular mechanisms and potential biomarkers for pulmonary arterial hypertension associated with congenital heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: